Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Sponsor
Novo Nordisk A/S
Study ID
NCT02321878
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions. No treatment given.

Study Details

This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.

Key Dates

Start date
Dec 15, 2014
Status verified
Aug 2017
Primary completion
Jun 16, 2017
Completion
Jun 16, 2017

Study Design

Enrollment
1,092 participants (actual)

Arms

  • Arm: Liraglutide

Primary Outcome Measure

Number of AEs (adverse events) [ Time Frame: Week 0-52 ]

Related Studies